business.financialpost.com
Valeant Pharmaceuticals International Inc downgraded: RBC analysts slash price target on the company by more than $100
Immense uncertainty lingering over Valeant forced RBC to lower its rating to ‘sector perform’ from ‘outperform’ and slash its price target to US$85 from US$194